Technology

Sol-Gel Technologies

$10.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-1.86%) As of 3:57 PM UTC today

Why Robinhood?

You can buy or sell SLGL and other stocks, options, and ETFs commission-free!

About SLGL

Sol-Gel Technologies Ltd. Ordinary Shares, also called Sol-Gel Technologies, is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel. The listed name for SLGL is Sol-Gel Technologies Ltd. Ordinary Shares.

CEO
Alon Seri-Levy, PhD
Employees
61
Headquarters
Ness Ziona, Tel Aviv
Founded
1997
Market Cap
233.69M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
18.52K
High Today
$10.66
Low Today
$10.16
Open Price
$10.57
Volume
7.10K
52 Week High
$14.25
52 Week Low
$5.00

Collections

SLGL Earnings

-$0.46
-$0.31
-$0.15
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 24, Pre-Market

You May Also Like

MUI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure